CV Sciences, Inc.
CVSIDrugs in Pipeline
4
Phase 3 Programs
1
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 0 past
No catalysts found.
CVT-E002 (Cold-FX); a natural health product
Upper Respiratory Infection
CVT E002 (Cold-fX)
Healthy
HT1001 extract of Panax quinquefolius L
Memory
CVT-E002 ginseng extract
Upper Respiratory Infection
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
CVT-E002 (Cold-FX); a natural health product | Phase 3 | Upper Respiratory Infection | - | - |
CVT E002 (Cold-fX) | Phase 2 | Healthy | - | - |
HT1001 extract of Panax quinquefolius L | Phase 2 | Memory | - | - |
CVT-E002 ginseng extract | Phase 2 | Upper Respiratory Infection | - | - |
Frequently asked questions
What is in CV Sciences, Inc.'s drug pipeline?→
CatalystAlert tracks 4 drug candidates in CV Sciences, Inc.'s (CVSI) pipeline across Phase 3, Phase 2. Its lead program is CVT-E002 (Cold-FX); a natural health product (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is CV Sciences, Inc.'s next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for CV Sciences, Inc. (CVSI) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track CVSI biotech catalysts?→
Add CVSI to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow CV Sciences, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.